Published online on: January 7, 2019 .
Abstract
Trabectedin (ET‑743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings.
In the present case report, two patients with advanced and metastatic uterine leiomyosarcomas (ULMS) with significant progression‑free survival (PFS) and overall survival (OS) administered Trabectedin as second and third line treatment are reported.
The first case received third line Trabectedin with a PFS of 24 months and an OS of 35 months.
The second case received second line Trabectedin with a PFS of 24 months and an OS of 30 months.
In addition, a good safety record was obtained in the long‑term administration of Trabectedin (more so in case 1 than case 2), with a good quality of life.